Heart Free Cash Flow Yield vs Capex To Revenue Analysis

HSCS Stock

USD 3.83 0.41 11.99%

Heart Test financial indicator trend analysis is much more than just examining Heart Test Laboratories latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Heart Test Laboratories is a good investment. Please check the relationship between Heart Test Free Cash Flow Yield and its Capex To Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heart Test Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Free Cash Flow Yield vs Capex To Revenue

Free Cash Flow Yield vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Heart Test Laboratories Free Cash Flow Yield account and Capex To Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Heart Test's Free Cash Flow Yield and Capex To Revenue is -0.96. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Heart Test Laboratories, assuming nothing else is changed. The correlation between historical values of Heart Test's Free Cash Flow Yield and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Heart Test Laboratories are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Free Cash Flow Yield i.e., Heart Test's Free Cash Flow Yield and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.96

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Heart Test's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Heart Test Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heart Test Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

At this time, Heart Test's Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.26 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.5 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	371.6K	243.2K	354.1K	242.9K
Depreciation And Amortization	26.6K	26.9K	95.1K	58.5K

Interest Expense Depreciation And Amortization

Heart Test fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.01	0.54	0.33	0.85	0.12	0.41	0.68	-0.83	-0.93	0.37	1.0	0.99	0.37	-0.07	1.0	0.99	-0.59	-0.17	0.57	-0.81	0.99	0.88	0.18	0.99	0.65
Short Long Term Debt Total	0.01		0.77	0.88	-0.51	-0.98	-0.75	0.55	0.54	-0.24	0.7	0.06	-0.11	0.72	0.98	0.06	-0.12	-0.65	0.97	-0.51	-0.51	0.06	-0.02	0.98	-0.09	-0.5
Other Current Liab	0.54	0.77		0.9	0.03	-0.68	-0.17	0.95	-0.03	-0.77	0.88	0.59	0.43	0.92	0.71	0.59	0.45	-0.94	0.69	0.14	-0.91	0.61	0.61	0.85	0.43	0.17
Total Current Liabilities	0.33	0.88	0.9		-0.2	-0.83	-0.43	0.79	0.21	-0.56	0.91	0.37	0.22	0.71	0.79	0.37	0.22	-0.72	0.78	-0.16	-0.73	0.36	0.33	0.94	0.21	-0.13
Total Stockholder Equity	0.85	-0.51	0.03	-0.2		0.62	0.7	0.25	-1.0	-0.65	-0.09	0.82	0.91	-0.09	-0.58	0.82	0.9	-0.15	-0.66	0.7	-0.41	0.81	0.72	-0.36	0.9	0.77
Net Tangible Assets	0.12	-0.98	-0.68	-0.83	0.62		0.81	-0.45	-0.64	0.09	-0.6	0.07	0.23	-0.62	-0.99	0.07	0.25	0.52	-0.98	0.59	0.37	0.09	0.11	-0.92	0.21	0.59
Property Plant And Equipment Net	0.41	-0.75	-0.17	-0.43	0.7	0.81		0.12	-0.76	-0.35	-0.11	0.38	0.48	-0.16	-0.79	0.38	0.53	0.06	-0.76	0.95	-0.09	0.43	0.58	-0.63	0.43	0.94
Current Deferred Revenue	0.68	0.55	0.95	0.79	0.25	-0.45	0.12		-0.27	-0.88	0.85	0.72	0.59	0.85	0.48	0.72	0.63	-0.91	0.46	0.42	-0.94	0.75	0.81	0.67	0.58	0.44
Net Debt	-0.83	0.54	-0.03	0.21	-1.0	-0.64	-0.76	-0.27		0.65	0.07	-0.8	-0.89	0.08	0.61	-0.8	-0.9	0.15	0.68	-0.76	0.4	-0.8	-0.75	0.39	-0.88	-0.82
Retained Earnings	-0.93	-0.24	-0.77	-0.56	-0.65	0.09	-0.35	-0.88	0.65		-0.66	-0.94	-0.88	-0.63	-0.14	-0.94	-0.91	0.8	-0.09	-0.58	0.95	-0.96	-0.9	-0.42	-0.87	-0.64
Accounts Payable	0.37	0.7	0.88	0.91	-0.09	-0.6	-0.11	0.85	0.07	-0.66		0.41	0.26	0.74	0.58	0.41	0.3	-0.74	0.61	0.16	-0.77	0.43	0.45	0.81	0.23	0.17
Cash	1.0	0.06	0.59	0.37	0.82	0.07	0.38	0.72	-0.8	-0.94	0.41		0.98	0.42	-0.02	1.0	0.98	-0.64	-0.11	0.56	-0.84	0.99	0.89	0.23	0.98	0.64
Non Current Assets Total	0.99	-0.11	0.43	0.22	0.91	0.23	0.48	0.59	-0.89	-0.88	0.26	0.98		0.25	-0.19	0.98	0.99	-0.49	-0.29	0.59	-0.73	0.97	0.86	0.06	1.0	0.68
Non Currrent Assets Other	0.37	0.72	0.92	0.71	-0.09	-0.62	-0.16	0.85	0.08	-0.63	0.74	0.42	0.25		0.7	0.42	0.3	-0.97	0.71	0.14	-0.82	0.48	0.51	0.77	0.26	0.15
Long Term Debt	-0.07	0.98	0.71	0.79	-0.58	-0.99	-0.79	0.48	0.61	-0.14	0.58	-0.02	-0.19	0.7		-0.02	-0.2	-0.61	0.99	-0.56	-0.42	-0.03	-0.06	0.92	-0.16	-0.56
Cash And Short Term Investments	1.0	0.06	0.59	0.37	0.82	0.07	0.38	0.72	-0.8	-0.94	0.41	1.0	0.98	0.42	-0.02		0.98	-0.64	-0.11	0.56	-0.84	0.99	0.89	0.23	0.98	0.64
Net Receivables	0.99	-0.12	0.45	0.22	0.9	0.25	0.53	0.63	-0.9	-0.91	0.3	0.98	0.99	0.3	-0.2	0.98		-0.53	-0.29	0.66	-0.76	0.98	0.89	0.05	0.99	0.74
Common Stock Shares Outstanding	-0.59	-0.65	-0.94	-0.72	-0.15	0.52	0.06	-0.91	0.15	0.8	-0.74	-0.64	-0.49	-0.97	-0.61	-0.64	-0.53		-0.58	-0.25	0.93	-0.68	-0.66	-0.73	-0.5	-0.27
Non Current Liabilities Total	-0.17	0.97	0.69	0.78	-0.66	-0.98	-0.76	0.46	0.68	-0.09	0.61	-0.11	-0.29	0.71	0.99	-0.11	-0.29	-0.58		-0.53	-0.38	-0.11	-0.11	0.91	-0.27	-0.54
Capital Lease Obligations	0.57	-0.51	0.14	-0.16	0.7	0.59	0.95	0.42	-0.76	-0.58	0.16	0.56	0.59	0.14	-0.56	0.56	0.66	-0.25	-0.53		-0.37	0.61	0.78	-0.37	0.55	0.99
Inventory	-0.81	-0.51	-0.91	-0.73	-0.41	0.37	-0.09	-0.94	0.4	0.95	-0.77	-0.84	-0.73	-0.82	-0.42	-0.84	-0.76	0.93	-0.38	-0.37		-0.86	-0.79	-0.65	-0.73	-0.43
Other Current Assets	0.99	0.06	0.61	0.36	0.81	0.09	0.43	0.75	-0.8	-0.96	0.43	0.99	0.97	0.48	-0.03	0.99	0.98	-0.68	-0.11	0.61	-0.86		0.92	0.22	0.97	0.68
Other Stockholder Equity	0.88	-0.02	0.61	0.33	0.72	0.11	0.58	0.81	-0.75	-0.9	0.45	0.89	0.86	0.51	-0.06	0.89	0.89	-0.66	-0.11	0.78	-0.79	0.92		0.13	0.85	0.82
Total Liab	0.18	0.98	0.85	0.94	-0.36	-0.92	-0.63	0.67	0.39	-0.42	0.81	0.23	0.06	0.77	0.92	0.23	0.05	-0.73	0.91	-0.37	-0.65	0.22	0.13		0.07	-0.34
Net Invested Capital	0.99	-0.09	0.43	0.21	0.9	0.21	0.43	0.58	-0.88	-0.87	0.23	0.98	1.0	0.26	-0.16	0.98	0.99	-0.5	-0.27	0.55	-0.73	0.97	0.85	0.07		0.64
Property Plant And Equipment Gross	0.65	-0.5	0.17	-0.13	0.77	0.59	0.94	0.44	-0.82	-0.64	0.17	0.64	0.68	0.15	-0.56	0.64	0.74	-0.27	-0.54	0.99	-0.43	0.68	0.82	-0.34	0.64

Click cells to compare fundamentals

Heart Test Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Heart Stock Analysis

When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Heart Free Cash Flow Yield vs Capex To Revenue Analysis

Free Cash Flow Yield vs Capex To Revenue

Free Cash Flow Yield vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Capex To Revenue

Heart Test fundamental ratios Correlations

Heart Test Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Heart Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Net Invested Capital	+ 1.0	Non Current Assets Total
Non Current Assets Total	+ 0.99	Total Assets
Net Receivables	+ 0.99	Total Assets

Net Debt	- 1.0	Total Stockholder Equity
Long Term Debt	- 0.99	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Net Tangible Assets	- 0.98	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.97	Non Currrent Assets Other
Other Current Assets	- 0.96	Retained Earnings